Tibet Pharma

What Tibet Pharma does

Tibet Pharmaceutical (西藏诺迪康药业股份有限公司 / Tibet Rhodiola Pharmaceutical Holding Co., SSE: 600211) is a publicly-listed Chinese pharmaceutical company incorporated on July 14, 1999 in Lhasa, Tibet Autonomous Region. Headquartered at the Lhasa Economic and Technological Development Zone with 501-1000 employees, the company operates five business segments — Modern Tibetan Medicine, Modern Chinese Medicine, Biopharmaceuticals, Chemical Drugs, and Big Health+ — and runs manufacturing or R&D operations in Lhasa, Chengdu, Guanghan, and Shanghai through wholly-owned subsidiaries. The company has been listed on the Shanghai Stock Exchange since July 21, 1999.

The portfolio is anchored on the Rhodiola-based Nuodikang (诺迪康) franchise: Rhodiola Capsules (National Class III new drug, China-exclusive) and Rhodiola Granules (National Class IV, China-exclusive) for Qi-deficiency-and-blood-stasis cardiovascular conditions including coronary heart disease and angina. The flagship biopharmaceutical is Recombinant Human Brain Natriuretic Peptide for injection (rhBNP / 新活素 / Neoactivin), a National Class I new drug — the highest regulatory tier in China — used for acute decompensated heart failure. The company also markets isosorbide mononitrate sustained-release tablets (IMDUR, acquired globally ex-US in 2016) and a small lineup of pediatric, hepatobiliary, hyperlipidemia, and neurasthenia products. R&D infrastructure includes a National Enterprise Technology Center and the National and Local Joint Engineering Research Center for Modernization of Tibetan Medicine. The Big Health+ segment packages Rhodiola extracts into consumer skincare, foot bath, and aromatic products, with the ultrasonic atomization device having won a 2019 Red Dot Award: Product Design.

Revenue is generated primarily through direct sales to hospitals, healthcare institutions, and retail pharmacies within China. Key products are listed on the National Medical Insurance Drug Catalog (rhBNP continuously since 2017 through 2025) and the National Essential Drug List, with pricing negotiated through national medical-insurance processes. Since 2015, commercial operations for rhBNP and the Rhodiola franchise have been entrusted to Shenzhen Kangzhe Medical. International revenue comes from the IMDUR portfolio (ex-US) and consumer Big Health+ products are sold through the company's own e-commerce platform. The company has also entered vaccines via Shanghai SynForce Biotechnology (2020) and holds a minority stake in Beijing Advanced Medical Technologies for medical devices.

Name

Tibet Pharma

Legal name

西藏诺迪康药业股份有限公司

Website

https://xzyy.cn

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Tibet Pharmaceutical is a Shanghai-listed Chinese pharmaceutical company that develops and manufactures Modern Tibetan Medicine, Modern Chinese Medicine, biopharmaceuticals, chemical drugs, and Big Health+ consumer products, primarily serving hospitals, retail pharmacies, and consumers in China and select international markets.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Herbal & Botanical Supplements (CRADAGAD), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Modern Tibetan medicine
• Cardiovascular pharmaceuticals
• Biopharmaceutical injections
• Rhodiola herbal products
• Chinese herbal medicine

Headquarters

HQ city

Lhasa

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products Sales: The company generates revenue through manufacturing and selling pharmaceutical products including Modern Tibetan Medicine, Modern Chinese Medicine, Biopharmaceuticals, and Chemical Drugs. Annual average sales revenue remained above RMB 1 billion. Key products include Rhodiola Capsules, Rhodiola Granules, rhBNP, and others.
2. Big Health Products: Revenue from wellness and health products including Rhodiola Moisturizing Essence, Rhodiola Incense, and Rhodiola Hydrosol derived from Tibetan wild Rhodiola.
3. IMDUR Product Licensing: In 2016, the company acquired IMDUR assets and its global brand (except US), expanding business layout globally and generating revenue from international cardiovascular drug market.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels4 records

Core offering

Tibet Pharma manufactures and sells proprietary pharmaceutical products across five segments: Modern Tibetan Medicine (Rhodiola Capsules, Rhodiola Granules, Shiwei Dida Capsules, Xueshan Jinluohan Pain-Relieving Paint), Modern Chinese Medicine (Pediatric Shuangqing Granules, Zhiqing Capsules, Shenzhi Capsules, Puyu Capsules), Biopharmaceuticals (Recombinant Human Brain Natriuretic Peptide / rhBNP for acute decompensated heart failure), Chemical Drugs (Isosorbide Mononitrate Sustained-release Tablets and IMDUR cardiovascular portfolio), and Big Health+ wellness products (Rhodiola Moisturizing Essence, foot bath powder, aromatics). Products are sold to hospitals, retail pharmacies, and consumers via the company's own e-commerce platform.

Product overview

Tibet Pharmaceutical (西藏诺迪康药业股份有限公司 / Tibet Rhodiola Pharmaceutical Holding Co., stock code: 600211) is a Shanghai Stock Exchange-listed pharmaceutical company established in 1999 and headquartered in Lhasa, Tibet. The company operates across five business segments: Modern Tibetan Medicine (现代藏药), Modern Chinese Medicine (现代中药), Biopharmaceuticals (生物制药), Chemical Drugs (化学药品), and Big Health+ (大健康+). Its product portfolio centers on the Rhodiola franchise — including 诺迪康胶囊 (Rhodiola Capsules, Class III new drug, China-exclusive) and 诺迪康颗粒 (Rhodiola Granules, Class IV, China-exclusive) — for cardiovascular conditions (Qi deficiency and blood stasis, coronary heart disease, angina). The biopharma flagship 注射用重组人脑利钠肽 (rhBNP / Recombinant Human Brain Natriuretic Peptide, Class I new drug, China-exclusive, brand name 新活素) targets acute decompensated heart failure. Additional core products span pediatric medicine (小儿双清颗粒), hepatobiliary therapy (石韦滴达胶囊), hyperlipidemia (脂清胶囊), pediatric intelligence (参志胶囊), neurasthenia (普育胶囊), and cardiovascular chemical drugs (单硝酸异山梨酯缓释片). The Big Health+ segment leverages Rhodiola's therapeutic properties into consumer wellness products including portable ultrasonic atomization moisturizing essences (with Red Dot Award-winning device designs), foot bath powders, and aromatics.

Differentiator

Problem solved

Functional benefit

Brands

• 诺迪康 (Nuodikang): Core pharmaceutical brand including Rhodiola Capsules, Rhodiola Granules, and related cardiovascular products

Products and services

• Rhodiola Capsules (诺迪康胶囊) Modern Tibetan medicine hard capsule; a National Class III new drug and China-exclusive product. Tonifies Qi, promotes blood circulation, invigorates pulses, and relieves pain. Indicated for chest impediment caused by Qi deficiency and blood stasis, including chest tightness, stinging/dull pain, palpitation, shortness of breath, and fatigue; used for coronary heart disease and angina pectoris. Each capsule 0.28g.
• Rhodiola Granules (诺迪康颗粒) Modern Tibetan medicine granules; a National Class IV traditional Chinese medicine and China-exclusive product. Tonifies Qi, promotes blood circulation, invigorates pulses, and relieves pain. Indicated for chest impediment caused by Qi deficiency and blood stasis, used for coronary heart disease and angina pectoris. Each bag 5g; dissolved in boiled water, 1 bag per dose, 3 times daily.
• Xueshan Jinluohan Pain-Relieving Paint (雪山金罗汉止痛涂膜剂) Modern Tibetan medicine topical liniment; a National Class III new drug. Activates blood, reduces swelling, and relieves pain. Indicated for acute and chronic soft tissue injuries, rheumatoid and rheumatoid arthritis, gout, periarthritis of shoulder, osteoproliferation-related limb joint pain and swelling, and neural headache. Applied topically 3 times daily.
• Pediatric Shuangqing Granules (小儿双清颗粒) Modern Chinese medicine granules; a National Class III new drug and China-exclusive product. Clears heat and detoxifies; harmonizes both exterior and interior. Used for pediatric exogenous diseases manifesting as fever, runny nose, red throat, thirst, dry stool, dark urine; acute upper respiratory infection. Age-dosed from infants to children over 7 years.
• Zhiqing Capsules (脂清胶囊) Modern Chinese medicine capsule. Promotes blood circulation and removes blood stasis; nourishes the liver and kidney. Indicated for essential (primary) hyperlipidemia with Yin deficiency in liver and kidney and blood stasis syndrome, with symptoms of dizziness, tinnitus, soreness of waist and knees, chest tightness, constipation. Dosage: 2 capsules 3 times daily for 6 weeks per course.
• Shenzhi Capsules (参志胶囊) Modern Chinese medicine hard capsule. Tonifies Qi and nourishes blood; clears heat and removes phlegm; awakens the mind and benefits intelligence. Used for pediatric mental retardation caused by phlegm and stasis accumulating heat and mind obstruction. Dosage: 5 capsules 3 times daily.
• Recombinant Human Brain Natriuretic Peptide for Injection (rhBNP / 新活素 Xinhuosu / Neoactivin) Biopharmaceutical injectable; a National Class I new drug and China-exclusive product. White powder or block form. Indicated for intravenous therapy in patients with acute decompensated heart failure (NYHA Class II and above). Loading dose via IV bolus followed by maintenance dose via IV drip. Each vial 0.5mg / 500U. Marketed under brand name Xinhuosu (新活素 / Neoactivin).
• Isosorbide Mononitrate Sustained-release Tablets (单硝酸异山梨酯缓释片) Chemical drug film-coated tablet (30mg pink, 60mg yellow). Indicated for long-term treatment of coronary heart disease, prevention of vasospastic and mixed angina, post-myocardial infarction treatment, and chronic heart failure long-term treatment. Normal dose 60mg once daily in the early morning, may be increased to 120mg.
• IMDUR Product Portfolio International first-line cardiovascular chemical drug portfolio; assets and brand acquired globally (excluding the US) by Tibet Pharma in 2016. Distributed through international channel partners to develop the global cardiovascular drug market.
• Shiwei Dida Capsules (十味蒂达胶囊) Modern Tibetan medicine capsule; a National Class IV new drug and China-exclusive product. Soothes the liver and regulates Qi; clears heat and detoxifies; benefits the gallbladder and dissolves calculi. Indicated for hypochondriac pain caused by dampness-heat of liver and gallbladder, chronic cholecystitis/cholelithiasis. Dosage: 2 capsules 3 times daily.
• Puyu Capsules (普育胶囊) Modern Chinese medicine hard capsule. Clears the heart and resolves phlegm; soothes the liver and relieves depression. Indicated for neurasthenia caused by liver depression transforming into fire, with symptoms of insomnia, dreaminess, upset heat and irritability. Dosage: 2-3 capsules 3 times daily.
• Rhodiola Moisturizing Essence (元氧 红景天保湿精华原液) Big Health+ portable skincare product. Rhodiola hydrosol made from Tibet wild Rhodiola via special extraction processes; anti-oxidative and pure natural. Delivered via ultrasonic atomization device that excites hydrosol into nanoscale molecules for enhanced skin absorption. Relieves fatigue and shortens alcohol metabolism time.
• Rhodiola Moisturizing Essence (Totoro-style Portable Device) Big Health+ portable skincare product variant with Totoro-shaped ultrasonic atomization device. Same Rhodiola hydrosol formulation delivered via nanoscale molecule atomization for enhanced skin and mucous membrane absorption.
• Rhodiola Secret Formula Foot Bath Powder (秘制香粉包) Big Health+ foot bath product. Made from wild Rhodiola harvested from the snow-capped plateau using a low-temperature cell-wall-breaking process; independently packaged. Used for foot bathing to improve microcirculation of capillaries in the feet and relieve soreness, distension, and numbness in the ankle and below caused by strain.
• Luxury Rhodiola Incense (红景天香豪华款) Big Health+ aromatic product. Made from Tibet wild Rhodiola with precious spices, using glazed backflow incense burner. After ignition, the aroma lasts long and refreshes the mind.

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• Sichuan Women & Children FoundationminorOthers · 10 July 2023Partnership for public welfare activity 'Benefiting Children to Welcome the Universiade Under the Leadership of CPC'. Company donated RMB 350,000 for children's education and cultural programs in Sichuan, Tibet, and Qinghai schools.
• Tibet Autonomous Region Medical Products AdministrationminorOthers · 29 December 2022Online communication meeting on policy consultation and technical guidance. Discussed drug production license, registration and circulation topics. Administration expressed support for company's development.
• Shanghai SynForce Biotechnology Co., Ltd.coreStrategic or Co-development Partner · 1 January 2020Established in 2020 with vaccine production base in Lingang New Area, Shanghai Pilot Free Trade Zone. Expands company's presence in biotech sector.
• Beijing Advanced Medical Technologies, Ltd. Inc.minorStrategic or Co-development Partner · 1 January 2020Company became shareholder to expand business into medical device sector.
• Tibet Oxygen Big Health Life Sciences Co., Ltd.coreStrategic or Co-development Partner · 1 January 2019Established to deeply explore therapeutic effects and healthcare of Tibetan medicine. Launches big health products combining traditional Tibetan medicine/TCM-based health maintenance with modern science and technology to achieve 'Healthy China' goals.
• Shenzhen Kangzhe MedicalcoreChannel Partner/ Reseller/ Distributor · 1 January 2015The company entrusted Shenzhen Kangzhe Medical with the operation of rhBNP and Rhodiola series products to leverage their advantages in operation and management for accelerated development of two pillar products. This partnership enabled faster market expansion of core products.
• Shenzhen Kangzhe Medical and Tibet Huaxi PharmaceuticalcoreStrategic or Co-development Partner · 1 January 2014Strategic alliance formed when Shenzhen Kangzhe Medical joined Tibet Rhodiola Pharmaceutical and partnered with Tibet Huaxi Pharmaceutical (main sponsor). Two major shareholders complemented each other's advantages to help company become bigger and stronger.

Scale indicators9 records

Recent moves9 records

Expansion highlights5 records

Broad incumbents

• Shanghai Pharmaceuticals Holding: One of China's largest pharmaceutical conglomerates, distributing and manufacturing a broad portfolio of chemical drugs, TCMs, and biopharmaceuticals. A broad incumbent whose cardiovascular and biotech portfolio overlaps with Tibet Pharma's, though at much larger scale and across many more therapeutic areas.
• Livzon Pharmaceutical Group: Diversified Chinese pharma manufacturer with biopharmaceuticals, TCM, and chemical drug franchises. Comparable in its mix of biologics and TCM, including cardiovascular and digestive therapeutic areas, with hospital-channel distribution.
• Jiangsu Hengrui Pharmaceuticals: China's largest innovative drug company, with proprietary injectables and a national hospital sales force. Comparable through its biopharmaceutical injectable franchise (e.g., heart and oncology products) that competes for the same hospital prescribers as rhBNP.
• Sino Biopharmaceutical: Hong Kong-listed Chinese pharma major with a diversified cardiovascular, hepatobiliary and biologic drug portfolio. Comparable in its hospital-channel cardiovascular franchise, NRDL-driven pricing model, and biopharma growth ambitions.

Direct peers

• Yunnan Baiyao Group: Iconic Chinese botanical/pharmaceutical company with proprietary exclusive formulations, a hospital-and-retail channel mix, and significant consumer healthcare (Big Health) exposure. Comparable as a publicly listed firm combining branded TCM drugs with a consumer wellness line.
• Tasly Pharmaceutical Group: Leading Chinese TCM and modern Chinese medicine manufacturer with a strong cardiovascular franchise (e.g., Compound Danshen/Salvia products). Comparable in product positioning (modernized TCM in cardiovascular care), hospital-channel GTM, and listed-company scale.
• China Traditional Chinese Medicine Holdings: Hong Kong-listed subsidiary of SinoPharm focused on modernized traditional Chinese medicine formulations, including cardiovascular and chronic-disease products. Directly comparable as a Chinese pharma company selling Class III/IV new TCM drugs through hospital and retail channels, competing with Tibet Pharmaceutical's Rhodiola and Shuangqing lines.
• Shijiazhuang Yiling Pharmaceutical: Specialized Chinese TCM and modernized Chinese medicine company with a strong cardiovascular franchise and proprietary Class I/II new drug certifications. Closely comparable in positioning (TCM-derived cardiovascular and chronic disease treatments) and in NRDL-driven commercialization.

Emerging players

• Sciwind Biosciences: Chinese biotech focused on metabolic and cardiometabolic biologics, including injectable therapies. Comparable as an emerging player in the cardiometabolic biologics space where rhBNP competes, though with a narrower therapeutic focus.
• Beijing Tide Pharmaceutical: Chinese pharmaceutical company specializing in injectable cardiovascular drugs with proprietary formulations. Comparable as a domestic injectable cardiovascular specialist competing in the same hospital prescribing environment as rhBNP.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/tibet-rhodiola-pharmaceutical-holding-co-

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tibet Pharma